Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The firm also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.
Follow-Up Questions
Who is the CEO of Hoth Therapeutics Inc?
Mr. Robb Knie is the President of Hoth Therapeutics Inc, joining the firm since 2017.
What is the price performance of HOTH stock?
The current price of HOTH is $1.38, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Hoth Therapeutics Inc?
Hoth Therapeutics Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Hoth Therapeutics Inc market cap?
Hoth Therapeutics Inc's current market cap is $18.2M
Is Hoth Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Hoth Therapeutics Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
